Literature DB >> 21320165

Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells.

Ka-Pan Lam1, Yu-Te Chu, Min-Sheng Lee, Huan-Nan Chen, Wei-Li Wang, Teck-Siang Tok, Yow-Yue Chin, Solomon Chih-Cheng Chen, Chang-Hung Kuo, Chih-Hsing Hung.   

Abstract

Short-acting β2-adrenoreceptor agonist (SABA) is the major asthma reliever as indicated in the GINA guidelines. Regulated on activation, normal T expressed and secreted (RANTES) is a chemokine that attracts eosinophils, mast cells, and basophils toward site of allergic inflammation. Interferon γ-inducible protein (IP)-10 is a Th1-related chemokine that is also important in asthmatic inflammation and also involved in our immune defense against pathogens. Bronchial epithelial cells are first-line barrier against invasive pathogen and also have immunomodulatory function. However, whether albuterol and fenoterol (two SABAs) have modulatory effects on RANTES and IP-10 expression in bronchial epithelial cells is unknown. The human bronchial epithelial cell lines, BEAS-2B cells, were pre-treated with different concentrations of albuterol, fenoterol or dibutyryl-cAMP (a cyclic AMP analog) before polyinosinic-polycytidylic acid (poly I:C) stimulation. In some condition, BEAS-2B cells were pre-treated with ICI-118551, a selective β2-adrenoreceptor antagonist, 30 min before albuterol or fenoterol treatment. The levels of RANTES and IP-10 were measured by ELISA. Intracellular signaling was investigated using cAMP assay, mitogen-activated protein kinase (MAPK) inhibitor, nuclear factor (NF)-κB inhibitor, and western blot. Albuterol and fenoterol suppressed poly I:C-induced RANTES and IP-10 expression of BEAS-2B cells. ICI-118551 could partly reverse the suppressive effects of albuterol and fenoterol on RANTES and IP-10 expression. Albuterol and fenoterol increased intracellular cAMP levels. Dibutyryl-cAMP conferred the similar effects of albuterol and fenoterol. Western blot revealed that albuterol suppressed p-ERK, p-JNK and pp38, and also their associated kinase expression. Albuterol had no effect on pp65 expression. Albuterol and fenoterol could suppress poly I:C-induced RANTES and IP-10 expression in human bronchial epithelial cells via at least partly the β2-adrenoreceptor-cAMP and the MAPK pathways, implicating that albuterol and fenoterol could exert anti-inflammatory effect and benefit asthmatic patients by suppressing RANTES and IP-10 expression. However, these suppressive effects of albuterol and fenoterol may inhibit the defense against viral infection.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320165     DOI: 10.1111/j.1399-3038.2010.01119.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  4 in total

Review 1.  Linking GATA-3 and interleukin-13: implications in asthma.

Authors:  Sheikh Rayees; Fayaz Malik; Syed Imran Bukhari; Gurdarshan Singh
Journal:  Inflamm Res       Date:  2013-12-22       Impact factor: 4.575

2.  Induction of the Matrix Metalloproteinase 13 Gene in Bronchial Epithelial Cells by Interferon and Identification of its Novel Functional Polymorphism.

Authors:  Yoichi Mashimo; Mika Sakurai-Yageta; Misa Watanabe; Takayasu Arima; Yoshinori Morita; Yuzaburo Inoue; Kazuki Sato; Toshiyuki Nishimuta; Shuichi Suzuki; Hiroko Watanabe; Akira Hoshioka; Minako Tomiita; Akiko Yamaide; Yoichi Kohno; Yoshitaka Okamoto; Naoki Shimojo; Akira Hata; Yoichi Suzuki
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  House dust mite allergen Der f 2 induces interleukin-13 expression by activating the PI3K/Akt pathway.

Authors:  Eun Ji Ro; Pu-Hyeon Cha; Hyun-Yi Kim; Yong-Hee Cho; Jung-Won Park; Joong-Soo Han; Kang-Yell Choi
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  The role of the liver X receptor in chronic obstructive pulmonary disease.

Authors:  Andrew Higham; Simon Lea; Jonathan Plumb; Barbara Maschera; Karen Simpson; David Ray; Dave Singh
Journal:  Respir Res       Date:  2013-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.